|
1
|
Harris SL and Levine AJ: The p53 pathway:
Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sherr CJ: Principles of tumor suppression.
Cell. 116:235–246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski
RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ and Young
KH: Dysfunction of the TP53 tumor suppressor gene in lymphoid
malignancies. Blood. 119:3668–3683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leroy B, Anderson M and Soussi T: TP53
mutations in human cancer: Database reassessment and prospects for
the next decade. Hum Mutat. 35:672–688. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Swerdlow SH, Campo E, Pileri SA, Harris
NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz
AD, et al: The 2016 revision of the World Health Organization
classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenquist R, Rosenwald A, Du MQ, Gaidano
G, Groenen P, Wotherspoon A, Ghia P, Gaulard P, Campo E and
Stamatopoulos K: European Research Initiative on CLL (ERIC) and the
European Association for Haematopathology (EAHP): Clinical impact
of recurrently mutated genes on lymphoma diagnostics:
State-of-the-art and beyond. Haematologica. 101:1002–1009. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iqbal J, Naushad H, Bi C, Yu J, Bouska A,
Rohr J, Chao W, Fu K, Chan WC and Vose JM: Genomic signatures in
B-cell lymphoma: How can these improve precision in diagnosis and
inform prognosis? Blood Rev. 30:73–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stefancikova L, Moulis M, Fabian P,
Ravcukova B, Vasova I, Muzik J, Malcikova J, Falkova I, Slovackova
J and Smardova J: Loss of the p53 tumor suppressor activity is
associated with negative prognosis of mantle cell lymphoma. Int J
Oncol. 36:699–706. 2010.PubMed/NCBI
|
|
9
|
Stefancikova L, Moulis M, Fabian P, Vasova
I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I,
et al: Prognostic impact of p53 aberrations for R-CHOP-treated
patients with diffuse large B-cell lymphoma. Int J Oncol.
39:1413–1420. 2011.PubMed/NCBI
|
|
10
|
Flaman JM, Frebourg T, Moreau V,
Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron
L and Benhattar J: A simple p53 functional assay for screening cell
lines, blood, and tumors. Proc Natl Acad Sci USA. 92:3963–3967.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Smardová J, Nemajerová A, Trbusek M,
Vagunda V and Kovarík J: Rare somatic p53 mutation identified in
breast cancer: A case report. Tumour Biol. 22:59–66. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ishioka C, Frebourg T, Yan YX, Vidal M,
Friend SH, Schmidt S and Iggo R: Screening patients for
heterozygous p53 mutations using a functional assay in yeast. Nat
Genet. 5:124–129. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Waridel F, Estreicher A, Bron L, Flaman
JM, Fontolliet C, Monnier P, Frebourg T and Iggo R: Field
cancerisation and polyclonal p53 mutation in the upper
aero-digestive tract. Oncogene. 14:163–169. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bouaoun L, Sonkin D, Ardin M, Hollstein M,
Byrnes G, Zavadil J and Olivier M: TP53 variations in human
cancers: New lessons from the IARC TP53 database and genomics Data.
Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grochova D, Vankova J, Damborsky J,
Ravcukova B, Smarda J, Vojtesek B and Smardova J: Analysis of
transactivation capability and conformation of p53
temperature-dependent mutants and their reactivation by amifostine
in yeast. Oncogene. 27:1243–1252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Halldórsdóttir AM, Lundin A, Murray F,
Mansouri L, Knuutila S, Sundström C, Laurell A, Ehrencrona H,
Sander B and Rosenquist R: Impact of TP53 mutation and 17p deletion
in mantle cell lymphoma. Leukemia. 25:1904–1908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Slotta-Huspenina J, Koch I, de Leval L,
Keller G, Klier M, Bink K, Kremer M, Raffeld M, Fend F and
Quintanilla-Martinez L: The impact of cyclin D1 mRNA isoforms,
morphology and p53 in mantle cell lymphoma: p53 alterations and
blastoid morphology are strong predictors of a high proliferation
index. Haematologica. 97:1422–1430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Beà S, Valdés-Mas R, Navarro A, Salaverria
I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, et
al: Landscape of somatic mutations and clonal evolution in mantle
cell lymphoma. Proc Natl Acad Sci USA. 110:18250–18255. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Meissner B, Kridel R, Lim RS, Rogic S, Tse
K, Scott DW, Moore R, Mungall AJ, Marra MA, Connors JM, et al: The
E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell
lymphoma. Blood. 121:3161–3164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J, Jima D, Moffitt AB, Liu Q, Czader
M, Hsi ED, Fedoriw Y, Dunphy CH, Richards KL, Gill JI, et al: The
genomic landscape of mantle cell lymphoma is related to the
epigenetically determined chromatin state of normal B cells. Blood.
123:2988–2996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nordström L, Sernbo S, Eden P, Grønbaek K,
Kolstad A, Räty R, Karjalainen ML, Geisler C, Ralfkiaer E,
Sundström C, et al: SOX11 and TP53 add prognostic information to
MIPI in a homogenously treated cohort of mantle cell lymphoma: a
Nordic Lymphoma Group study. Br J Haematol. 166:98–108. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Delfau-Larue MH, Klapper W, Berger F,
Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C,
Ribrag V, et al: European Mantle Cell Lymphoma Network: High-dose
cytarabine does not overcome the adverse prognostic value of CDKN2A
and TP53 deletions in mantle cell lymphoma. Blood. 126:604–611.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stöcklein H, Hutter G, Kalla J, Hartmann
E, Zimmermann Y, Katzenberger T, Adam P, Leich E, Höller S,
Müller-Hermelink HK, et al: Genomic deletion and promoter
methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle
cell lymphoma. J Hematop. 1:85–95. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu-Monette ZY, Wu L, Visco C, Tai YC,
Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, et
al: Mutational profile and prognostic significance of TP53 in
diffuse large B-cell lymphoma patients treated with R-CHOP: Report
from an International DLBCL Rituximab-CHOP Consortium Program
Study. Blood. 120:3986–3996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu TX, Young KH, Xu W and Li JY: TP53
dysfunction in diffuse large B-cell lymphoma. Crit Rev Oncol
Hematol. 97:47–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
